As a class, sodium–glucose transporter ... patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary mechanism of action is inhibition of SGLT2 in the proximal ...
Lexicon Pharmaceuticals has reported that LX4211, an inhibitor of the sodium-dependent glucose transporter 2 (SGLT2; also known as SLC5A2), significantly improved glycaemic control in a Phase II ...
SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback